Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

This study has been completed.
Celgene Corporation
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre Identifier:
First received: May 21, 2008
Last updated: October 14, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2012
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):